| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/08/2004 | EP1453828A2 Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| 09/08/2004 | EP1453815A1 Metabotropic glutamate receptor-5 modulators |
| 09/08/2004 | EP1453795A2 Esters and amides as ppar-alpha agonists |
| 09/08/2004 | EP1453743A2 Pharmaceutical product with an adsorbent |
| 09/08/2004 | EP1453548A2 Compositions for and methods of treating and preventing sirs/sepsis |
| 09/08/2004 | EP1453544A2 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 09/08/2004 | EP1453541A1 Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| 09/08/2004 | EP1453540A2 Modulation of lir function to treat rheumatoid arthritis |
| 09/08/2004 | EP1453533A1 Migration of hematopoietic stem cells and progenitor cells to th e liver |
| 09/08/2004 | EP1453532A2 Taojiks as modifiers of the beta-catenin pathway and methods of use |
| 09/08/2004 | EP1453528A2 Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 09/08/2004 | EP1453526A2 Pharmaceutical composition for topical treatment of skin disorders and skin wounds |
| 09/08/2004 | EP1453521A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 09/08/2004 | EP1453520A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances |
| 09/08/2004 | EP1453518A1 Pharmaceutical composition for the treatment of disorders of non-human mammals |
| 09/08/2004 | EP1453513A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| 09/08/2004 | EP1453510A2 Neurotransmitter balance chemotherapy |
| 09/08/2004 | EP1453508A1 Tempamine compositions and use against cellular oxidative damage |
| 09/08/2004 | EP1453504A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation |
| 09/08/2004 | EP1453501A1 N- aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity |
| 09/08/2004 | EP1453497A1 Use for the treatment of gastroesophageal reflux disease |
| 09/08/2004 | EP1453495A2 Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists |
| 09/08/2004 | EP1453487A1 Pharmaceutical dosage form with multiple coatings |
| 09/08/2004 | EP1453481A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 09/08/2004 | EP1453431A2 Method and apparatus for the stimulation of hair growth |
| 09/08/2004 | EP1397503A4 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 09/08/2004 | EP1294867B1 Human site-1 protease promoter |
| 09/08/2004 | EP1292313B1 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 09/08/2004 | EP1272637A4 A METHOD FOR SCREENING FOR AUTOIMMUNE DISEASE BY IDENTIFYING POLYMORPHISMS IN IL-12 p40 |
| 09/08/2004 | EP1267853B1 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 09/08/2004 | EP1225897B1 Composition for treatment of constipation and irritable bowel syndrome |
| 09/08/2004 | EP1176971B1 Use of phyllanthus for treating chronic inflammatory and fibrotic processes |
| 09/08/2004 | EP1084114B1 Isothiazole derivatives useful as anticancer agents |
| 09/08/2004 | EP1039874B1 Compositions and methods for treatment of alopecia |
| 09/08/2004 | EP1001802B1 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor |
| 09/08/2004 | EP0960127A4 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/08/2004 | EP0835127B1 Composition containing a myelin-associated glycoprotein (mag) inhibitor which comprises an altered or mutated form of mag |
| 09/08/2004 | EP0758232B1 Methods for modulating t cell responses by manipulating intracellular signal transduction |
| 09/08/2004 | CN1527838A Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha |
| 09/08/2004 | CN1527836A Antiviral agents for treatment of flaviviridae infections |
| 09/08/2004 | CN1527831A Antagonists of MCP-q function and method of use thereof |
| 09/08/2004 | CN1527723A Methods for treating or preventing skin disorders using CD2-binding agents |
| 09/08/2004 | CN1527718A Method for short-term and long-term drug dosimetry |
| 09/08/2004 | CN1527713A Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 09/08/2004 | CN1527712A Active ingredient combination for medicamentous therapy of nicotine dependency |
| 09/08/2004 | CN1527711A Active substance combination for medicamentous therapy of habituation of or habitual material or narcotics |
| 09/08/2004 | CN1527709A Therapeutic combinations for cardiovascular and inflammatory indications |
| 09/08/2004 | CN1527707A The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 09/08/2004 | CN1527704A Compositions and method of administering tubulin binding agents for the treatment of ocular diseases |
| 09/08/2004 | CN1526449A Method of eliminating and inhibiting bitter of medicine |
| 09/08/2004 | CN1526448A Medicine and method for the treatment of anorectal disorders |
| 09/08/2004 | CN1526398A Compound blood pressure reducing prepn containing angiotonin converzyme inhibitor, calcium ion agonist and Estazolam |
| 09/08/2004 | CN1165764C Anti PSMA antibody or antigen binding part, and their use |
| 09/08/2004 | CN1165536C Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 09/08/2004 | CN1165343C Indications for use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses |
| 09/08/2004 | CN1165310C Drug-(combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid and an inhibitor,inducer or substrate of P450 |
| 09/08/2004 | CN1165308C Compositions and method for reducing respiratory depression and attendant side effect of mu opioid compounds |
| 09/08/2004 | CN1165298C New use of compounds as antibacterial agents |
| 09/08/2004 | CN1165293C New oral formulation for 5-HT4 agonists or antagonists |
| 09/07/2004 | US6787573 Antiviral therapy |
| 09/07/2004 | US6787568 Antibiotic/analgesic formulation and a method of making this formulation |
| 09/07/2004 | US6787558 Neuropeptide y receptor antagonists, for treating arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity |
| 09/07/2004 | US6787553 Sexual disorders; vasodilation |
| 09/07/2004 | US6787529 Synergistic mixture of vitamin d and corticosteroids; skin disorders |
| 09/07/2004 | US6787526 Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| 09/07/2004 | US6787521 Skin disorders; kidney and liver disorders |
| 09/07/2004 | US6787519 Methods of treating disorders related to apoE |
| 09/07/2004 | US6787517 Agent and methods for treating pain |
| 09/07/2004 | US6787346 Kinase capable of site-specific phosphorylation of IκBα |
| 09/07/2004 | US6787342 Paste formulations |
| 09/07/2004 | US6787335 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer. |
| 09/07/2004 | US6787321 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 09/07/2004 | US6787164 Composition and method for treating the effects of diseases and maladies |
| 09/07/2004 | US6787157 Multiphase active ingredient-containing formulations |
| 09/03/2004 | CA2456410A1 Stabilised pharmaceutical composition comprising an extented release non-steroidal anti-inflammatory agent and an immediate release prostaglandin |
| 09/02/2004 | WO2004074284A1 Oxazole-derivatives as ppar agonists |
| 09/02/2004 | WO2004073727A1 Method for improving qol and composition therefor |
| 09/02/2004 | WO2004073721A1 A food-supplement composition suitable for promoting iron absorption |
| 09/02/2004 | WO2004073719A1 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
| 09/02/2004 | WO2004073715A1 Antifungal agents |
| 09/02/2004 | WO2004073712A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | WO2004073706A1 Drug for reducing side effects in ribavirin interferon combination therapy |
| 09/02/2004 | WO2004073704A1 New combination |
| 09/02/2004 | WO2004073695A1 Therapeutic system comprising amoxicillin and clavulanic acid |
| 09/02/2004 | WO2004073654A2 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
| 09/02/2004 | WO2004073623A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | WO2004073614A2 Combination therapy for the treatment of immunoinflammatory disorders |
| 09/02/2004 | WO2004073606A2 Sulfonamide derivatives as ppar modulators |
| 09/02/2004 | WO2004073420A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 09/02/2004 | WO2004060361A3 Combination of reboxetine and a cyclooxygenase-2 inhibitor |
| 09/02/2004 | WO2004052285A3 Fat regulation |
| 09/02/2004 | WO2004043378A3 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 09/02/2004 | WO2004036224A3 Screening method |
| 09/02/2004 | WO2004032881A3 Implantation of encapsulated biological materials for treating diseases |
| 09/02/2004 | WO2004030656B1 Method of preparing pharmaceutical dosage forms containing multiple active ingredients |
| 09/02/2004 | WO2004018000A3 Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents |
| 09/02/2004 | WO2004014851A3 Tyrosine kinase inhibitors |
| 09/02/2004 | WO2004002421A3 Method for the treatment of multiple sclerosis |
| 09/02/2004 | WO2003084539A3 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| 09/02/2004 | WO2003084344A3 Method of improving absorption of vitamin e by a pet animal |